Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis

54Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Anticoagulation is a rational approach to the treatment of sepsis-associated consumptive coagulopathy, but its application is limited because of the risk of excessive bleeding. Factor XI (FXI) contributes substantially to pathological blood coagulation (thrombosis), whereas it contributes only modestly to normal hemostasis. We found that FXI-deficient mice have reduced coagulopathy and increased survival relative to FXI-expressing wild-type mice during cecal ligation and puncture-induced acute peritonitis/sepsis. This finding suggests that FXI contributes to coagulopathy and/or inflammation during sepsis and that pharmacologic inhibition of FXI activity may alter the course and outcome of some infections. © 2008 by the Infectious Diseases Society of America. All rights reserved.

Cite

CITATION STYLE

APA

Tucker, E. I., Gailani, D., Hurst, S., Cheng, Q., Hanson, S. R., & Gruber, A. (2008). Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. Journal of Infectious Diseases, 198(2), 271–274. https://doi.org/10.1086/589514

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free